SteadyMed (STDY) Receiving Somewhat Negative News Coverage, Study Shows
Media stories about SteadyMed (NASDAQ:STDY) have trended somewhat negative this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. SteadyMed earned a daily sentiment score of -0.12 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.9349697787374 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
STDY has been the topic of several recent analyst reports. Zacks Investment Research upgraded SteadyMed from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. ValuEngine lowered SteadyMed from a “hold” rating to a “sell” rating in a research note on Friday, September 1st.
Shares of SteadyMed (STDY) traded down 1.47% during trading on Monday, hitting $3.35. The stock had a trading volume of 6,503 shares. SteadyMed has a 1-year low of $2.25 and a 1-year high of $4.10. The company’s market cap is $88.96 million. The firm’s 50 day moving average is $3.41 and its 200 day moving average is $3.41.
SteadyMed (NASDAQ:STDY) last issued its quarterly earnings data on Friday, August 11th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.01). SteadyMed had a negative return on equity of 226.48% and a negative net margin of 3,179.76%. The business had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.26 million. Equities research analysts anticipate that SteadyMed will post ($1.56) EPS for the current fiscal year.
SteadyMed Company Profile
SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).
Receive News & Ratings for SteadyMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.